Bull
$120.31
Scenario price
$85.850
-3.837 (-4.47%)At close
Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. It is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. It provides periodic onsite services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally.
Transcat Inc is currently not a strong buy due to its recent price drop and mixed financial indicators. The current price is $85.85, which is below the analyst price target of $95, indicating potential upside. However, the RSI is at 29.77, suggesting the stock is oversold, and the forward P/E ratio is high at 51.02, indicating that the stock may be overvalued at this time. The main risk is the recent negative earnings trend, with a net income drop to -1.1 million in Q3 2026, which raises concerns about future profitability.
Northland
$95
2026-08-05
Northland
2026-08-05
Price Target
$95
Northland
$95
2025-10-23
Northland
2025-10-23
Price Target
$95
Lake Street
$105
2025-07-10
Lake Street
2025-07-10
Price Target
$105
H.C. Wainwright
$116
2025-05-21
H.C. Wainwright
2025-05-21
Price Target
$116
HC Wainwright & Co.
$106
2025-01-29
HC Wainwright & Co.
2025-01-29
Price Target
$106
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Transcat to Attend Multiple Investor Conferences in 2026

Surge in Options Trading Volume for CAVA and Qiagen

Transcat Reports 22% Revenue Growth in Q1 2027 Earnings Call

Transcat Q1 Earnings Exceed Expectations

Transcat to Release Q1 FY2027 Results on August 4, 2026
Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. It is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. It provides periodic onsite services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally. It operates in the Industrials sector (INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & EL industry).
Transcat Inc is currently not a strong buy due to its recent price drop and mixed financial indicators. The current price is $85.85, which is below the analyst price target of $95, indicating potential upside. However, the RSI is at 29.77, suggesting the stock is oversold, and the forward P/E ratio is high at 51.02, indicating that the stock may be overvalued at this time. The main risk is the recent negative earnings trend, with a net income drop to -1.1 million in Q3 2026, which raises concerns about future profitability.
2 analysts cover TRNS: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 100.00.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.